| Species |
Human |
| Protein Construction |
HLA-A*03:01&B2M&gp100 (ALLAVGATK) Monomer[Gly25-Thr305 (HLA-A*03:01), Ile21-Met119 (B2M) and ALLAVGATK peptide]
Accession # NP_002107.3(HLA-A*03:01)&P61769(B2M)&ALLAVGATK |
His |
Avi |
| N-term |
|
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
50.15 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 51-60 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
Immunization against the ALLAVGATK peptide may occur in melanoma patients and that the immunogenicity of this peptide is similar to that of the majority of melanoma differentiation antigens defined to date. Therefore, the use of ALLAVGATK in active immunotherapy for HLA-A3 melanoma patients, for whom no other immunogenic peptide has been so far described, remains a distinct possibility, providing that patients treated in vivo with this peptide develop a better in vitro response than already demonstrated for HLA-A2 epitopes generated from this same antigenic protein. |
| Synonyms |
gp100 (ALLAVGATK) |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
